Biomarkers for ovarian cancer detection and therapy.
Despite advances in surgical technologies and the development of more effective chemotherapeutics, epithelial ovarian cancer (EOC) remains the leading cause of death in women with gynecologic malignancies. The high mortality and morbidity associated with EOC is mostly attributed to the inability to detect the disease before it is widely disseminated throughout the abdominal cavity. In the past decade, tremendous efforts have been taken to search for novel biomarkers that will detect EOC at an early stage, which may also serve as new targets for the prevention and control of metastasis. Here, we review recent developments in EOC early detection and targeted therapy, as well as new technologies for the discovery of novel biomarkers.
Dutta
Sonia
S
Department of Obstetrics, Gynecology and Reproductive Sciences, Mount Sinai School of Medicine, New York, NY, USA.
Wang
Feng-qiang
FQ
Phalen
Adrien
A
Fishman
David A
DA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D011379:Prognosis
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor